Elevated serum soluble Fas levels in the various stages of hepatitis C virus-induced liver disease

Journal of International Medical Research

Volumn 31, Issue 5, 2003, Pages 384-391

  Ozaslan E ^a,b   Kilicarslan A ^a   Simsek H ^a   Tatar, G ^a   Kirazli, S ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Hepatitis C virus; Liver disease; Pathogenesis; Serum soluble Fas antigen (sFas)

Indexed keywords

ALANINE AMINOTRANSFERASE; FAS ANTIGEN; INTERFERON; RIBAVIRIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN DETECTION; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION;

EID: 0142211392     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000303100505     Document Type: Article

References (31)

1. Alter MJ, Mast EE: The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23: 437-455.
2. Seeff LB, Buskell-Bales Z, Wright EC, Durako SJ, Alter HJ, Iber FL, et al: Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, Blood Institute Study Group. N Engl J Med 1992; 327: 1906-1911.
3. Chiaramonte M, Stroffolini T, Vian A, Stazi MA, Floreani A, Lorenzoni U, et al: Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer 1999; 85: 2132-2137.
4. Thompson CB: Apoptosis in the pathogenesis and treatment of disease. Science 1995; 267: 1456-1462.
5. Roberts J, Searle J, Cooksley W: Histological patterns of prolonged hepatitis C infection. Gastroenterol Jpn 1993; 28: 37-41.
6. Kagi D, Vignaux F, Ledermann B, Burki K, Depraetere V, Nagata S, et al: Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 1994; 265: 528-530.
7. Koziel MJ, Dudley D, Wong JT, Dienstag J, Houghton M, Ralston R et al: Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol 1992; 149: 3339-3344.
8. Nagata S, Golstein P: The Fas death factor. Science 1995; 267: 1449-1456.
9. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al: Lethal effects of the anti-Fas antibody in mice. Nature 1993; 364: 806-809.
10. Adachi M, Watanabe-Fukunaga R, Nagata S: Aberrant transcription caused by the insertion of an early transposable element in the intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci U S A 1993; 90: 1756-1760.
11. Hiramatsu N, Hayashi N, Katayama K, Mochizuki K, Kawanishi Y, Kasahara A, et al: Immunohistochemical detection of Fas antigen in liver tissues of patients with chronic hepatitis C. Hepatology 1994; 19: 1354-1359.
12. Mita E, Hayashi N, Iio S, Takehara T, Hijioka T, Kasahara A, et al: Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun 1994; 204: 468-474.
13. Cascino I, Fiucci G, Papoff G, Ruberti G: Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol 1995; 154: 2706-2713.
14. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, et al: Protection from Fas-mediated apoptosis by soluble form of the Fas molecule. Science 1994; 263: 1759-1762.
15. Jodo S, Kobayashi S, Kayagaki N, Ogura N, Feng Y, Amasaki Y, et al: Serum levels of soluble Fas/APO1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol 1997; 107: 89-95.
16. Knipping E, Debatin KM, Stricker K, Heilig B, Eder A, Krammer PH: Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood 1995; 85: 1562-1569.
17. Midis GP, Shen Y, Owen-Schaub LB: Elevated soluble Fas (sFas) levels in non-hematopoietic human malignancy. Cancer Res 1996; 56: 3870-3874.
18. Iio S, Hayashi N, Mita E, Ueda K, Mochizuki K, Horamatsu N, et al: Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol 1998; 29: 517-523.
19. Ohkawa K, Hiramatsu N, Mochizuki K, Mita E, Iio S, Yoshihara H, et al: Significance of serum soluble Fas antigen level in chronic hepatitis C patients treated with interferon: relationship to the therapeutic response. J Gastroenterol Hepatol 2001; 16: 1009-1014.
20. Galle PR: Apoptosis in liver disease. J Hepatol 1997; 27: 405-412.
21. Suzuki K, Endo R, Nakamura N, Yatomi T, Iwai M, Abe K, et al: Serum levels of soluble Fas ligand in patients with acute and fulminant hepatitis: relationship with soluble Fas, tumor necrosis factor alpha and TNF receptor-1. Hepatol Res 2000; 17: 19-30.
22. Macias J, Sanchez-Quijano A, Pineda JA, Abad MA, Rubio A, Rosa R, et al: Minimal liver injury in chronic hepatitis C virus infection is associated with low levels of soluble TNF-alpha/Fas receptors and acquisition in childhood. Liver 2001; 21: 410-414.
23. Jodo S, Kobayashi S, Nakajima Y, Mitsunaga T, Nakayama N, Ogura N, et al: Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol 1998; 112: 166-171.
24. Desmet VJ, Gerber M, Hoofnagel JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: diagnosis, grading, and staging. Hepatology 1994; 19: 1513-1520.
25. Pawlotsky JM: Hepatitis C virus infection: virus/host interactions. J Viral Hepat 1998; 5(Suppl 1): 3-8.
26. Toyoda M, Kakizaki S, Horiguchi N, Sato K, Takayama H, Takagi H, et al: Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis C. Liver 2000; 20: 305-311.
27. Calabrese F, Pontisso P, Pettenazzo E, Benvegnu L, Vario A, Chemello L, et al: Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. Hepatology 2000; 31: 1153-1159.
28. Pianko S, Patella S, Ostapowicz G, Desmond P, Sievert W: Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. J Viral Hepat 2001; 8: 406-413.
29. Yoneyama K, Goto T, Miura K, Mikami K, Ohshima S, Nakane K, et al: The expression of Fas and Fas ligand, and the effects of interferon in chronic liver diseases with hepatitis C virus. Hepatol Res 2002; 24: 327-337.
30. Seishima M, Takemura M, Saito K, Ando K, Noma A: Increased serum soluble Fas (sFas) concentrations in HCV-positive patients with liver cirrhosis. J Hepatol 1997; 27: 424-427.
31. Okazaki M, Hino K, Fujii K, Kobayashi N, Okita K: Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C. Dig Dis Sci 1996; 41: 2453-2458.